PARADISE-MI Secondary Prevention Algorithm
Clinical decision-support aid for reviewing whether a recent myocardial infarction resembles the PARADISE-MI trial population and for organizing secondary-prevention considerations. It does not calculate an individualized treatment effect.
Patient and index-event profile
Enter information from the index acute myocardial infarction (AMI).
Complete the patient profile
The assessment will appear here after valid inputs are submitted.
Criteria assessment
Secondary-prevention considerations
This result checks selected trial-profile characteristics only; it is not a validated prediction model or a substitute for the complete protocol eligibility assessment. Confirm clinical stability, laboratory values, contraindications, timing, and the full trial criteria before applying evidence to an individual patient.
About PARADISE-MI
PARADISE-MI compared sacubitril/valsartan with ramipril in patients with a recent acute MI complicated by LVEF ≤40%, transient pulmonary congestion requiring treatment, or both, plus at least one prespecified risk-enhancing factor. The trial's primary endpoint was not significantly reduced with sacubitril/valsartan versus ramipril.
Risk-enhancing factors used in this tool
| Factor | Trial criterion |
|---|---|
| Age | ≥70 years |
| Renal function | eGFR <60 mL/min/1.73 m² |
| Diabetes | Diabetes mellitus present |
| Prior MI | Previous myocardial infarction |
| Atrial fibrillation | Associated with index MI |
| LVEF | <30% |
| Killip class | Class III or IV |
| STEMI without reperfusion | No reperfusion within 24 hours |
Interpreting the result
The tool reports whether the entered data satisfy the core profile and at least one risk-enhancing factor. It does not establish that the patient met every trial inclusion/exclusion criterion, predict the benefit of ARNI, or prescribe a drug.
Clinical context
After MI, secondary prevention should be individualized according to coronary anatomy, revascularization, bleeding and ischemic risk, LV function, comorbidities, and current guidelines.
- Use evidence-based lipid-lowering therapy and reassess LDL-C to guide intensification.
- Choose antiplatelet and, when indicated, anticoagulant therapy according to ACS context, thrombotic risk, and bleeding risk.
- Address blood pressure, smoking, physical activity, diet, adherence, and cardiac rehabilitation.
- For established HFrEF, implement guideline-directed therapy as tolerated and indicated, including renin–angiotensin system inhibition/ARNI, evidence-based beta-blocker, MRA, and SGLT2 inhibitor as appropriate.
- Do not infer ARNI superiority after MI from PARADISE-MI alone. For established HFrEF, apply the relevant HF guideline and individual clinical context.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.